- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 16, Issue 35, 2010
Current Pharmaceutical Design - Volume 16, Issue 35, 2010
Volume 16, Issue 35, 2010
-
-
Editorial [Hot topic: Anti-Angiogenic Agents (Executive Editor: Maurizio Botta and Anna Di Donna)]
More LessAngiogenesis has been described as one of the hallmarks of cancer, playing an essential role in tumor growth, invasion and metastasis. Antiangiogenic therapy was initially perceived as a “magic bullet” that could eventually be used for the treatment of any type of cancer. For this reason inhibition of angiogenesis has become a major challenge in the development of new anticancer agents, with a countless number Read More
-
-
-
Alternative Splicing: A Promising Target for Pharmaceutical Inhibition of Pathological Angiogenesis?
Authors: Carine Munaut, Alain C. Colige and Charles A. LambertIn eukaryotes, genes consist in coding sequences (exons) interspersed with non-coding ones (introns). The regulation of alternative inclusion/exclusion of exons, or part of exons, during the maturation of the pre-mRNA into mRNA (alternative splicing) allows a dramatic increase of the protein versus the gene repertoire. In a number of cases, alternative splicing decision generates proteins with distinct, sometimes o Read More
-
-
-
Oxidative Stress in Tumor Angiogenesis - Therapeutic Targets
Authors: Magdalena Tertil, Alicja Jozkowicz and Jozef DulakHistorically, oxidative stress was recognized to contribute to cancer development uniquely by induction of genomic instability. However, recent research has provided multiple evidence that reactive oxygen species and other free radicals, such as nitric oxide, often produced at elevated levels within tumor tissue, may function as signaling molecules that initiate and/or modulate the different regulatory pathways involved i Read More
-
-
-
Insulin, Thrombin, ERK1/2 Kinase and Vascular Smooth Muscle Cells Proliferation
Vascular smooth muscle cells (VSMC) respond to arterial wall injury by intimal proliferation and play a key role in atherogenesis by proliferating and migrating excessively in response to repeated injury, such as hypertension and atherosclerosis. In contrast, fully differentiated, quiescent VSMC allow arterial vasodilatation and vasoconstriction. Exaggerated and uncontrolled VSMC proliferation appears therefore to be a common Read More
-
-
-
CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization
Authors: S. Liekens, D. Schols and S. HatseChemokines are key players in the attraction and activation of leukocytes and are thus implicated in the recruitment of immune cells at sites of infection and/or inflammation. They exert their action by binding to seven-transmembrane G protein-coupled receptors. The chemokine stromal cell-derived factor-1 (SDF-1)/CXCL12 represents the single natural ligand for the chemokine receptor CXCR4. CXCL12 possesses angioge Read More
-
-
-
Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies
Authors: Michele Moschetta, Marta Cesca, Francesca Pretto and Raffaella GiavazziAngiogenesis is associated with tumor development and malignancy and is a validated target for cancer treatment. Preclinical and clinical evidence substantiates the feasibility of combining angiogenesis inhibitors with conventional anticancer therapy. This review discusses recent progress in combining antiangiogenic drugs, mainly acting on the VEGF/VEGFR pathway, with chemotherapy and other conventional therapies. Strat Read More
-
-
-
Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Authors: Ana R. Quesada, Miguel Angel Medina, Ramon Munoz-Chapuli and Angel Luis G. PonceAngiogenesis has been described as one of the hallmarks of cancer, playing an essential role in tumor growth, invasion, and metastasis. Antiangiogenic therapy was initially perceived as a “magic bullet” that could eventually be used for the treatment of any type of cancer. For this reason inhibition of angiogenesis has become a major challenge in the development of new anticancer agents, with a countless number Read More
-
-
-
Imaged-based High-Throughput Screening for Anti-Angiogenic Drug Discovery
Authors: Lasse Evensen, Wolfgang Link and James B. LorensRecent developments in high-content screening (HCS) technologies make it an attractive alternative for anti-angiogenic drug discovery. HCS integrates high-throughput methodologies with automated multicolor fluorescence microscopy to collect quantitative morphological and molecular data from complex biological systems. Organotypic systems based on primary vascular cells model many facets of angiogenesis. The ad Read More
-
-
-
Using Insights into Pim1 Structure to Design New Anticancer Drugs
Authors: Silvia Schenone, Cristina Tintori and Maurizio BottaHuman Pim1 (proviral integration site for Moloney murine leukemia virus) kinase is a 313-amino acid serine-threonine kinase that possesses several biological functions in cell survival, proliferation and differentiation, and its overexpression has been observed in a number of human cancers. Indeed, this kinase is a proto-oncogene that has been implicated in early transformation and tumor progression, especially in hematopoi Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
-
Volume 16 (2010)
- Issue 38
- Issue 37
- Issue 36
- Issue 35
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 7
- Issue 6
- Issue 5
- Issue 4
- Issue 3
- Issue 2
- Issue 1
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
